469 related articles for article (PubMed ID: 33861315)
1. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Terpos E; Trougakos IP; Gavriatopoulou M; Papassotiriou I; Sklirou AD; Ntanasis-Stathopoulos I; Papanagnou ED; Fotiou D; Kastritis E; Dimopoulos MA
Blood; 2021 Jul; 137(26):3674-3676. PubMed ID: 33861315
[No Abstract] [Full Text] [Related]
2. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.
Ludwig H; San-Miguel J; Munshi N; Sonneveld P; Mateos MV; Moreau P; Terpos E
Am J Hematol; 2021 Aug; 96(8):896-900. PubMed ID: 34057243
[No Abstract] [Full Text] [Related]
3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
4. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
6. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
Albach FN; Burmester GR; Biesen R
Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
[No Abstract] [Full Text] [Related]
7. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
[No Abstract] [Full Text] [Related]
8. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Golding B; Lee Y; Golding H; Khurana S
Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
[No Abstract] [Full Text] [Related]
9. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
[TBL] [Abstract][Full Text] [Related]
10. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
Naranbhai V; St Denis KJ; Lam EC; Ofoman O; Garcia-Beltran WF; Mairena CB; Bhan AK; Gainor JF; Balazs AB; Iafrate AJ;
Cancer Cell; 2022 Jan; 40(1):103-108.e2. PubMed ID: 34990570
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
12. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.
Harrington P; de Lavallade H; Doores KJ; O'Reilly A; Seow J; Graham C; Lechmere T; Radia D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison CN; McLornan DP
Leukemia; 2021 Dec; 35(12):3573-3577. PubMed ID: 34023850
[No Abstract] [Full Text] [Related]
13. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.
Terpos E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Malandrakis P; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
Blood Cancer J; 2021 Aug; 11(8):138. PubMed ID: 34341335
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
[TBL] [Abstract][Full Text] [Related]
15. The long road.
Cohen J
Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
[No Abstract] [Full Text] [Related]
16. Can immune responses predict which vaccines work best?
Cohen J
Science; 2021 Jul; 373(6551):142-143. PubMed ID: 34244387
[No Abstract] [Full Text] [Related]
17. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Falsey AR; Frenck RW; Walsh EE; Kitchin N; Absalon J; Gurtman A; Lockhart S; Bailey R; Swanson KA; Xu X; Koury K; Kalina W; Cooper D; Zou J; Xie X; Xia H; Türeci Ö; Lagkadinou E; Tompkins KR; Shi PY; Jansen KU; Şahin U; Dormitzer PR; Gruber WC
N Engl J Med; 2021 Oct; 385(17):1627-1629. PubMed ID: 34525276
[No Abstract] [Full Text] [Related]
18. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing SARS-CoV-2.
Poeschla E
Elife; 2020 Dec; 9():. PubMed ID: 33320086
[TBL] [Abstract][Full Text] [Related]
20. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
Edara VV; Pinsky BA; Suthar MS; Lai L; Davis-Gardner ME; Floyd K; Flowers MW; Wrammert J; Hussaini L; Ciric CR; Bechnak S; Stephens K; Graham BS; Bayat Mokhtari E; Mudvari P; Boritz E; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Douek DC; Sahoo MK; Sibai M; Solis D; Webby RJ; Jeevan T; Fabrizio TP
N Engl J Med; 2021 Aug; 385(7):664-666. PubMed ID: 34233096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
